(SNN) Smith & Nephew SNATS - Ratings and Ratios

Smith & Nephew plc, a global medical technology company, specializes in developing, manufacturing, and marketing medical devices and services. Headquartered in Watford, United Kingdom, the company operates in over 100 countries, serving healthcare providers across the globe. Established in 1856, Smith & Nephew has a long-standing reputation for innovation in medical devices. Its product portfolio spans three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

The Orthopaedics segment offers a wide range of products, including knee and hip implants for joint replacement and revision surgeries. Its trauma and extremities portfolio includes internal and external fixation devices for fracture stabilization and deformity correction. The company also provides reconstruction products for joint repair and replacement procedures. In Sports Medicine & ENT, Smith & Nephew delivers minimally invasive solutions for joint repair, including instruments, technologies, and implants for soft tissue injuries and degenerative conditions in the shoulder, knee, hip, and small joints. Its arthroscopic enabling technologies include fluid management systems, visualization equipment, and tissue resection devices. Additionally, the company offers solutions for ear, nose, and throat (ENT) surgeries.

In Advanced Wound Management, Smith & Nephew provides products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its portfolio includes advanced wound bioactives, such as biologics and bioactive technologies for debridement and dermal repair, as well as regenerative medicine products like skin, bone graft, and cartilage substitutes. The company also offers advanced wound care devices, such as negative pressure wound therapy systems and hydrosurgery solutions. Smith & Nephews products are designed to improve patient outcomes and reduce healthcare costs.

For more information, visit their website: https://www.smith-nephew.com.

3-Month Forecast:

Technical Outlook: SNNs stock price is currently trading near its 20-day SMA of 26.69, with a last price of 26.16. The 50-day and 200-day SMAs are 27.14 and 27.09, respectively, indicating a neutral to slightly bearish trend. The ATR of 0.73 suggests moderate volatility. Over the next three months, the stock is expected to consolidate within the 25-28 range, with potential resistance at 27.50 and support at 25.50.

Fundamental Outlook: With a market cap of $11.31 billion, SNN is well-positioned in the healthcare equipment sector. Its P/E ratio of 27.50 reflects premium valuation, while the forward P/E of 12.08 indicates expected earnings growth. The P/B ratio of 2.15 and P/S ratio of 1.95 suggest the stock is fairly valued relative to its peers. Return on equity (RoE) of 11.59% highlights moderate profitability. Over the next quarter, SNN is expected to maintain stable growth, supported by its diversified product portfolio and strong market presence.